Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.

ABSTRACT: Allogeneic hematopoietic stem cell transplantation (HSCT) offers the best chance for relapse-free survival to most patients with acute myeloid leukemia (AML). It may be performed during complete remission or delayed until after the first relapse because of relevant treatment-related morbidity and mortality. The measurable residual disease (MRD) status at HSCT adds refined prognostic information to the assigned European LeukemiaNet (ELN) 2017 genetic risk at diagnosis. We analyzed 580 patients with AML who underwent allogeneic HSCT during either the first (79%) or second (21%) remission. Although, because of common treatment strategies, some adverse risk characteristics, such as monosomal or complex karyotypes, were less frequent in patients who underwent transplant in the second remission,

SUBMITTER: Jentzsch M 

PROVIDER: S-EPMC9636320 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature